Product Description
The EyeGate II Delivery System and EGP-437 combination product, is being evaluated for the treatment of pain and inflammation in patients having undergone cataract surgery with implantation of a monofocal posterior chamber IOL (intraocular lens).
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ocular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kiora Pharmaceuticals
Company Location: WALTHAM MA 02452
Company CEO: Brian M. Strem
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Iridocyclitis|Uveitis, Anterior
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EGP-437-006 | P3 |
Completed |
Uveitis, Anterior|Iridocyclitis |
2018-04-20 |
73% |